Seattle Genetics, Inc. (SGEN) Reports Fourth Quarter And Year 2013 Financial Results
2/12/2014 8:23:52 AM
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline, collaborator updates and upcoming milestones.
Help employers find you! Check out all the jobs and post your resume.
comments powered by